Stock Code: Star Lake Bioscience Co.Inc.Zhaoqing Guangdong(600866) stock abbreviation: Star Lake Bioscience Co.Inc.Zhaoqing Guangdong(600866) No.: pro 2022016 Star Lake Bioscience Co.Inc.Zhaoqing Guangdong(600866)
Special report on the deposit and use of raised funds
The board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear individual and joint liabilities for the authenticity, accuracy and completeness of its contents.
According to the reply on approving Star Lake Bioscience Co.Inc.Zhaoqing Guangdong(600866) issuing shares to Zhang Guoliang and others to purchase assets and raise supporting funds (zjxk [2019] No. 98) issued by the CSRC on January 18, 2019, the company privately issued 38072562 ordinary shares (A shares) to raise matching funds, with a par value of RMB 1.00 per share and a subscription price of RMB 4.41 per share. The information about this raising and the deposit and actual use of the raised funds as of December 31, 2021 are reported as follows:
1、 Basic information of raised funds
The total amount of funds raised by the non-public offering company is 16789999842 yuan. After deducting the issuance expenses of underwriting, recommendation and other intermediaries, the actual net amount of funds raised is 15821549604 yuan. All the raised funds have been received and verified by Dahua Certified Public Accountants (special general partnership) with “Dahua Yan Zi [2019] No. 000135” capital verification report.
As of December 31, 2021, all the raised funds have been settled, and the company has invested 16318070114 yuan in the raised funds, including 1022749996 yuan for intermediary issuance, 13790000000 yuan for equity consideration, and 1505320118 yuan for the construction project of Chongqing R & D center. In September 2021, the company transferred the balance of the above special account (including interest income) totaling RMB 515903506 to the company’s own fund account for permanent replenishment of working capital, and completed the cancellation procedures of the special account, and the company terminated the tripartite supervision agreement on raised funds and the quadripartite supervision agreement on the storage of raised funds signed with the sponsor and the deposit banks of all parties. For the above matters of permanently replenishing working capital with the surplus raised funds, see the announcement on the closing of investment projects with raised funds and permanently replenishing working capital with the surplus raised funds (2021047).
2、 Management of raised funds
In order to regulate the management and use of the company’s raised funds, improve the efficiency and efficiency of the use of funds, and protect the interests of investors, the company, in accordance with the company law of the people’s Republic of China, the securities law of the people’s Republic of China, the stock listing rules of Shanghai Stock Exchange, the guidelines for self discipline supervision of listed companies No. 1 – standardized operation and other laws and regulations, and in combination with the actual situation, The company has formulated the management system of Star Lake Bioscience Co.Inc.Zhaoqing Guangdong(600866) raised funds (hereinafter referred to as the “management system”), which stipulates the storage, use, change, management and supervision of the raised funds, and implements the special account management of the raised funds.
According to the requirements of the management system and in combination with the business needs of the company, the company has opened special accounts for raised funds in China Construction Bank Corporation(601939) Zhaoqing branch, Bank Of China Limited(601988) Zhaoqing branch and Wenjiang Branch of Yibin commercial bank. The company, together with the sponsor Anxin Securities Co., Ltd., signed the tripartite supervision agreement on raised funds with China Construction Bank Corporation(601939) Zhaoqing branch and Bank Of China Limited(601988) Zhaoqing branch in April 2019; In December 2019, it signed the four party supervision agreement on the storage of special account for raised funds with Gaojiang branch of Yibin commercial bank and Sichuan Jiuling Pharmaceutical Technology Co., Ltd., a subsidiary of Yibin commercial bank, which defined the rights and obligations of all parties. There is no significant difference between the regulatory agreement and the model regulatory agreement of Shanghai Stock Exchange, and the company has strictly complied with the raised funds.
During the reporting period, the investment projects of the raised funds have been closed. The company cancels the special account of the raised funds, and transfers the remaining funds (including interest income) to the company’s own fund account for permanent replenishment of working capital.
3、 Actual use of raised funds in 2021
(I) during the reporting period, the actual use of the company’s raised funds is detailed in the attached table “use of raised funds”.
(II) during the reporting period, there was no advance investment and replacement of the investment project with the raised funds.
(III) during the reporting period, the company did not temporarily supplement working capital with idle raised funds.
(IV) during the reporting period, the company did not conduct cash management on idle raised funds and invest in related products.
(V) during the reporting period, the company will permanently supplement the working capital with the surplus raised capital of 515903506 yuan.
4、 Change the use of funds of raised investment projects
During the reporting period, the company did not change the raised investment projects or transfer or replace the raised investment projects.
5、 Problems in the use and disclosure of raised funds
During the reporting period, the information about the use of raised funds disclosed by the company was timely, true, accurate and complete, and there were no violations in the use and management of raised funds.
6、 Concluding opinions of the assurance report issued by the accounting firm on the deposit and use of the company’s annual raised funds
ShineWing Certified Public Accountants (special general partnership) believes that the special report on the annual storage and use of Star Lake Bioscience Co.Inc.Zhaoqing Guangdong(600866) raised funds has been prepared in accordance with the relevant provisions of Shanghai Stock Exchange, which truthfully reflects the actual storage and use of Star Lake Bioscience Co.Inc.Zhaoqing Guangdong(600866) raised funds in 2021 in all major aspects. 7、 Concluding comments on the special verification report issued by the recommendation institution on the deposit and use of the company’s annual raised funds
According to the special verification report to be issued by Anxin Securities Co., Ltd. on the deposit and use of the company’s raised funds in 2021: Star Lake Bioscience Co.Inc.Zhaoqing Guangdong(600866) the deposit and use of the raised funds in 2021 comply with the relevant laws and regulations of China Securities Regulatory Commission and Shanghai Stock Exchange on the deposit and use of raised funds, and there is no violation of relevant laws and regulations.
It is hereby announced.
Board of directors
March 29, 2022
Attached table: use of raised funds
Unit: RMB 10000
Total amount of funds raised in the current year: 876.00
Total amount of raised funds with changed purposes—
Raised funds with changed purposes – the proportion of the total amount of raised funds invested in the total amount of 1631807
By the end of the period, the raised funds of the changed items have been invested accumulatively. By the end of the period, whether the invested projects have reached the target of feasible committed investment projects in the current year, Including the promised investment amount after the adjustment of the Ministry’s committed investment, the cumulative amount invested by the end of the current year and the committed investment progress (%) (4) the total amount of expected distribution change realized by the fixed use condition (1) the difference between the input amount (2) the input amount (3) = (2) / (1) Significant change in status date benefit = (2) – (1)
Payment for M & A of Sichuan Jiujiu Pharmaceutical Technology Co., Ltd. in February 2019 no 137900013790001379000 — 1379000 — 100.00 for use on January 1
Equity consideration of the company
Whether to pay the intermediary fees related to this transaction 150 Yihua Healthcare Co.Ltd(000150) Yihua Healthcare Co.Ltd(000150) 000 — 102275 477.25 100.00 is not applicable
Chongqing R & D center will be built in June 2021. If it is not suitable, it will not be set up. If it is not suitable, it will be used for 150 Yihua Healthcare Co.Ltd(000150) 000 876.14150532 – 5.32 100.00 months
Total — 167900016790001679000 876.141631807 471.93 ———–
The reason for not reaching the planned progress is not applicable
The description of major changes in the feasibility of the project is not applicable
The advance investment and replacement of the investment projects with raised funds are not applicable
The temporary replenishment of working capital with idle raised funds is not applicable
Cash management is conducted for idle raised funds, and the investment of related products is not applicable
During the reporting period of permanent replenishment of working capital or repayment of bank loans with raised funds, the company will permanently replenish working capital with the surplus raised funds of 515903506 yuan.
The amount of the balance of raised funds and the reasons for its formation are different between the actual intermediary expenses and the expected intermediary expenses.
Other uses of raised funds are not applicable
